[Proteomics analysis of bone marrow cells of acute myeloid leukemia M2a and prognostic significance thereof].
To investigate the relationship between the distinct expression of proteins in the leukemic cells of leukemia AML-M(2)a patients before inducible treatment and that of the patients with relapse and the prognosis by proteomics. The bone marrow mononuclear cells (BMMNC) from 17 patients with leukemia AML-M(2)a before inductive treatment were divided into 3 groups according to the duration of CCR(1): Group A (n = 11) with the CCR(1) duration exceeding 12 months, Group B (n = 6) with the CCR(1) duration less than 6 months, and Group C, including the 3 cases of Group B with relapse. The proteins of the BMMNC were separated by two-dimensional electrophoresis, part of the differentially-expressed proteins were identified by matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). 6 differentially-expressed proteins were identified between Groups A and B by MALDI-TOF-MS: tubulin-specific chaperone B, myeloperoxidase, the CH domain of human transgelin-2, glutathione S-transferase, zinc finger protein, and glyceraldehyde-3-phosphate dehydrogenase. Three differentially-expressed proteins were identified in Group C: NAD (P) H dehydrogenase, hypothetical protein, and HES1. The expression level of distinct proteins of leukemic cells of leukemia AML-M(2)a patients before inductive treatments is associated with the prognosis. The proteins of the BMMNC of the patients would change when relapse occurs.